Latest Prasugrel Stories
Clinical Risk Assessment Plus Platelet Function Testing Identifies High-Risk Patients in Whom a Tailored Approach to Potent Antiplatelet Treatment May Potentially Be Beneficial SAN
Compared to Clopidogrel, Prasugrel Did Not Have a Higher Risk of Bleeding at 90 Days SAN DIEGO, May 8, 2015 /PRNewswire/ -- Prasugrel (Effient®) is more likely to be given to lower-risk
MarketOptimizer.org adds new report "Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" to its store.
DALLAS, September 7, 2014 /PRNewswire/ -- MarketOptimizer.org adds "Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023", a new research report to its
Rapid CYP2C19 Testing for Personalized Antiplatelet Therapy in 600-Patient Clinical Trial with Spartan Bioscience (PRWEB) March 18, 2014 Spartan Bioscience
Rapid CYP2C19 Testing for Heart Attack Patients Using Antiplatelet Drugs in 150-Patient Clinical Trial With Spartan Bioscience Ottawa, Ontario (PRWEB) December
Spartan Bioscience announces 2,000-patient clinical trial of rapid DNA testing for heart attack patients using antiplatelet drugs. Ottawa, Ontario (PRWEB) November
- A woman chauffeur.
- A woman who operates an automobile.